Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Roy Barry Tishler, Ph.D., M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Roy Tishler and Robert Haddad.
Roy Tishler
Connection Strength
7.655
Robert Haddad
  1. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer. 2009 Oct 01; 115(19):4514-23.
    View in: PubMed
    Score: 0.419
  2. Cetuximab added to docetaxel, cisplatin, 5-fluorouracil Induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study. J Clin Oncol. 2008 May 20; 26(15_suppl):6001.
    View in: PubMed
    Score: 0.381
  3. Multidisciplinary approach to cancer treatment: focus on head and neck cancer. Dent Clin North Am. 2008 Jan; 52(1):1-17, vii.
    View in: PubMed
    Score: 0.371
  4. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1036-44.
    View in: PubMed
    Score: 0.331
  5. Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. Am J Clin Oncol. 2006 Apr; 29(2):153-7.
    View in: PubMed
    Score: 0.328
  6. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 02 01; 28(3):468-478.
    View in: PubMed
    Score: 0.241
  7. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1563-1570.
    View in: PubMed
    Score: 0.224
  8. Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. Ann Oncol. 2012 Sep; 23(9):2391-2398.
    View in: PubMed
    Score: 0.212
  9. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol. 2019 03 01; 30(3):471-477.
    View in: PubMed
    Score: 0.201
  10. IMRT-based treatment of unknown primary malignancy of the head and neck: Outcomes and improved toxicity with decreased mucosal dose and larynx sparing. Head Neck. 2019 04; 41(4):959-966.
    View in: PubMed
    Score: 0.199
  11. Patient-oriented toxicity endpoints after head and neck reirradiation with intensity modulated radiation therapy. Oral Oncol. 2017 10; 73:160-165.
    View in: PubMed
    Score: 0.181
  12. Comparative Analysis of MicroRNA Expression among Benign and Malignant Tongue Tissue and Plasma of Patients with Tongue Cancer. Front Oncol. 2017; 7:191.
    View in: PubMed
    Score: 0.181
  13. Highlights in Head and Neck Cancer. JAMA Oncol. 2017 04 01; 3(4):441-442.
    View in: PubMed
    Score: 0.176
  14. Acupuncture for Chemoradiation Therapy-Related Dysphagia in Head and Neck Cancer: A Pilot Randomized Sham-Controlled Trial. Oncologist. 2016 12; 21(12):1522-1529.
    View in: PubMed
    Score: 0.168
  15. Patterns of failure after reirradiation with intensity-modulated radiation therapy and the competing risk of out-of-field recurrences. Oral Oncol. 2016 10; 61:19-26.
    View in: PubMed
    Score: 0.168
  16. Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience. Head Neck. 2016 04; 38 Suppl 1:E1618-24.
    View in: PubMed
    Score: 0.160
  17. Trastuzumab for the treatment of salivary duct carcinoma. Oncologist. 2013; 18(3):294-300.
    View in: PubMed
    Score: 0.132
  18. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013 Mar; 14(3):257-64.
    View in: PubMed
    Score: 0.132
  19. Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy. Ann Oncol. 2012 Sep; 23(9):2391-2398.
    View in: PubMed
    Score: 0.124
  20. Acupuncture for dysphagia after chemoradiation in head and neck cancer: rationale and design of a randomized, sham-controlled trial. Contemp Clin Trials. 2012 Jul; 33(4):700-11.
    View in: PubMed
    Score: 0.124
  21. Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e215-22.
    View in: PubMed
    Score: 0.117
  22. Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys. 2011 Aug 01; 80(5):1405-11.
    View in: PubMed
    Score: 0.114
  23. Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):308-14.
    View in: PubMed
    Score: 0.113
  24. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer. 2010 Oct 15; 116(20):4761-8.
    View in: PubMed
    Score: 0.112
  25. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol. 2010 Feb; 21(2):342-347.
    View in: PubMed
    Score: 0.105
  26. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2009 Sep 20; 27(27):4448-53.
    View in: PubMed
    Score: 0.104
  27. Retropharyngeal nodes in hypopharynx cancer on positron emission tomography. J Clin Oncol. 2007 Feb 10; 25(5):599-601.
    View in: PubMed
    Score: 0.087
  28. Dysphagia after sequential chemoradiation therapy for advanced head and neck cancer. Otolaryngol Head Neck Surg. 2006 Jun; 134(6):916-22.
    View in: PubMed
    Score: 0.083
  29. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2006 Jun; 132(6):678-81.
    View in: PubMed
    Score: 0.083
  30. Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006 May; 132(5):526-31.
    View in: PubMed
    Score: 0.083
  31. Integrating novel agents into the curative treatment of head and neck cancer. Expert Rev Anticancer Ther. 2006 Feb; 6(2):157-9.
    View in: PubMed
    Score: 0.081
  32. Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer. Am J Clin Oncol. 2005 Aug; 28(4):371-8.
    View in: PubMed
    Score: 0.078
  33. Rate of complete pathological responses (pCR) to docetaxel/cisplatin/5-fluorouracil (TPF) induction chemotherapy in patients with newly diagnosed, locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2005 Jun; 23(16_suppl):5511.
    View in: PubMed
    Score: 0.077
  34. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol. 2004 Dec; 31(6):778-85.
    View in: PubMed
    Score: 0.075
  35. A phase I/II study of docetaxel (D) and concomitant boost radiation (CBR) for patients with squamous cell cancer of the head and neck (SCCHN) following induction chemotherapy (IC). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5548.
    View in: PubMed
    Score: 0.073
  36. Organ preservation for patients treated with induction chemotherapy (IC) followed by radiation therapy (RT) or chemoradiation (CRT) for advanced stage squamous cell carcinoma of the larynx (SCCL). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5600.
    View in: PubMed
    Score: 0.073
  37. Nonsurgical treatment of laryngeal cancer. N Engl J Med. 2004 Mar 04; 350(10):1049-53; author reply 1049-53.
    View in: PubMed
    Score: 0.071
  38. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer. 2003 Jan 15; 97(2):412-8.
    View in: PubMed
    Score: 0.066
  39. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist. 2003; 8(1):35-44.
    View in: PubMed
    Score: 0.066
  40. Association between radiation dose to organs at risk and acute patient reported outcome during radiation treatment for head and neck cancers. Head Neck. 2022 Mar 31.
    View in: PubMed
    Score: 0.062
  41. Oligometastatic adenoid cystic carcinoma: Correlating tumor burden and time to treatment with outcomes. Head Neck. 2022 03; 44(3):722-734.
    View in: PubMed
    Score: 0.061
  42. Exposed bone in patients with head and neck cancer treated with radiation therapy: An analysis of the Observational Study of Dental Outcomes in Head and Neck Cancer Patients (OraRad). Cancer. 2022 02 01; 128(3):487-496.
    View in: PubMed
    Score: 0.060
  43. Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. Oral Oncol. 2021 01; 112:105087.
    View in: PubMed
    Score: 0.056
  44. Patient reported outcomes in patients with head and neck cancer treated with concurrent chemoradiation with weekly versus bolus cisplatin. Head Neck. 2020 12; 42(12):3670-3677.
    View in: PubMed
    Score: 0.056
  45. A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. Int J Radiat Oncol Biol Phys. 2021 01 01; 109(1):134-144.
    View in: PubMed
    Score: 0.056
  46. The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. Oncologist. 2020 07; 25(7):598-608.
    View in: PubMed
    Score: 0.054
  47. Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. Oral Oncol. 2020 07; 106:104690.
    View in: PubMed
    Score: 0.054
  48. Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2020 06; 105:104676.
    View in: PubMed
    Score: 0.054
  49. Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2019 10; 28(10):1660-1667.
    View in: PubMed
    Score: 0.052
  50. A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):132-139.
    View in: PubMed
    Score: 0.051
  51. Everolimus in Anaplastic Thyroid Cancer: A Case Series. Front Oncol. 2019; 9:106.
    View in: PubMed
    Score: 0.050
  52. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):137-145.
    View in: PubMed
    Score: 0.048
  53. The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 11; 22(11):1413.
    View in: PubMed
    Score: 0.046
  54. The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline. Oncologist. 2017 03; 22(3):343-350.
    View in: PubMed
    Score: 0.044
  55. Salivary and serum HPV antibody levels before and after definitive treatment in patients with oropharyngeal squamous cell carcinoma. Cancer Biomark. 2017; 19(2):129-136.
    View in: PubMed
    Score: 0.043
  56. Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. Cancer. 2016 Dec 01; 122(23):3632-3640.
    View in: PubMed
    Score: 0.042
  57. Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. Br J Cancer. 2016 07 12; 115(2):252-60.
    View in: PubMed
    Score: 0.042
  58. Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. J Immunother Cancer. 2016; 4:32.
    View in: PubMed
    Score: 0.042
  59. Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer. Head Neck. 2016 10; 38(10):1530-8.
    View in: PubMed
    Score: 0.041
  60. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2016 06 15; 22(12):2939-49.
    View in: PubMed
    Score: 0.040
  61. Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Oncol Pract. 2015 Mar; 11(2):151-4.
    View in: PubMed
    Score: 0.038
  62. Ensuring head and neck oncology patients receive recommended pretreatment dental evaluations. J Clin Oncol. 2014 Oct 20; 32(30_suppl):100.
    View in: PubMed
    Score: 0.037
  63. Success of endoscopic pharyngoesophageal dilation after head and neck cancer treatment. Laryngoscope. 2013 Dec; 123(12):3066-73.
    View in: PubMed
    Score: 0.034
  64. Organ preservation for adenoid cystic carcinoma of the larynx. Oncologist. 2013; 18(5):579-83.
    View in: PubMed
    Score: 0.033
  65. Swallowing function following postchemoradiotherapy neck dissection: review of findings and analysis of contributing factors. Otolaryngol Head Neck Surg. 2011 Sep; 145(3):428-34.
    View in: PubMed
    Score: 0.030
  66. Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):e813-8.
    View in: PubMed
    Score: 0.029
  67. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011 Feb; 12(2):153-9.
    View in: PubMed
    Score: 0.029
  68. Utilizing computed tomography as a road map for designing selective and superselective neck dissection after chemoradiotherapy. Otolaryngol Head Neck Surg. 2010 Sep; 143(3):367-74.
    View in: PubMed
    Score: 0.028
  69. Combined antegrade and retrograde esophageal dilation for head and neck cancer-related complete esophageal stenosis. Laryngoscope. 2010 Feb; 120(2):261-6.
    View in: PubMed
    Score: 0.027
  70. Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009 Nov 01; 75(3):725-33.
    View in: PubMed
    Score: 0.025
  71. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol. 2009 May; 20(5):921-7.
    View in: PubMed
    Score: 0.025
  72. Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Nov 15; 72(4):1110-8.
    View in: PubMed
    Score: 0.024
  73. Sequential therapy for locally advanced larynx and hypopharynx cancer: Subgroup analysis from the TAX 324 Study. J Clin Oncol. 2008 May 20; 26(15_suppl):6031.
    View in: PubMed
    Score: 0.024
  74. Phase I study of panitumumab + chemoradiotherapy (CRT) for head and neck cancer (HNC). J Clin Oncol. 2008 May 20; 26(15_suppl):6007.
    View in: PubMed
    Score: 0.024
  75. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007 Oct 25; 357(17):1705-15.
    View in: PubMed
    Score: 0.023
  76. Chemoradiation-induced cell loss in human submandibular glands. Laryngoscope. 2005 Jun; 115(6):958-64.
    View in: PubMed
    Score: 0.019
  77. Endoscopic management of hypopharyngeal stenosis after organ sparing therapy for head and neck cancer. Laryngoscope. 2004 Nov; 114(11):1924-31.
    View in: PubMed
    Score: 0.019
  78. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004 Oct; 26(10):890-6.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.